key: cord-0920479-krnnd0x9 authors: Moosazadeh, Mahmood; Mousavi, Tahoora title: Combination therapy of tocilizumab and steroid for COVID‐19 patients: A meta‐analysis date: 2021-12-07 journal: J Med Virol DOI: 10.1002/jmv.27489 sha: 45308d864b626baa26b48595e9a8494f4a984e5b doc_id: 920479 cord_uid: krnnd0x9 The coagulation markers, pro‐inflammatory cytokines (such as IL‐2R, IL‐6, IL‐10, and TNF‐a) and lymphopenia are associated with the severity of coronavirus disease 2019 (COVID‐19) disease. The use of anti‐inflammatory agents, such as corticosteroids (CS) or tosilizumab (TCZ), has been suggested for the treatment of advanced stage of COVID‐19 and the reduction of mechanical ventilators and mortality. The aim of this meta‐analysis is to determine the role of combination therapy with tocilizumab and steroids in COVID‐19 patients. Relevant studies were found using online international databases, and suitable studies were selected and assessed by two independent researchers. The quality of all papers was determined by a checklist. Heterogeneity assay among the primary studies was evaluated by Cochran's Q‐test and I2 index. The statistical analyses were done using the Stata ver. 14 package (StataCorp) software. Publication bias was estimated through Egger's test, and the impact of each study on the overall estimate was assessed by sensitivity analysis. Five studies were entered into this meta‐analysis. The results of these studies showed that the risk of death for COVID‐19 patients treated with the combination of corticosteroids and tocilizumab compared to tocilizumab and the control group was 0.74 (95% confidence interval [CI]: 0.36–1.50) and 0.48 (95% CI: 0.31–0.74), respectively. This meta‐analysis showed that the risk of death in COVID‐19 patients who were treated with corticosteroids and tocilizumab was lower than the tocilizumab alone and control groups (26% and 52%, respectively). Respiratory Distress Syndrome (ARDS) is considered as an acute syndrome of lung inflammation and is the most common cause of death in this group of patients. 7, 8 Due to the inflammatory status in COVID- 19 , steroids have been used as immunomodulatory agents. 9 Recently, several studies have been done on the clinical benefits of steroids and corticosteroids and interferon inhibitors in COVID-19 patients. 10 In addition regarding viral infection, there are some guidelines that have been suggested for the use of glucocorticoids and other immune-regulating agents. 11 It is suggested that patients undergoing corticosteroid therapy as well as patients treated with interleukin appear to be better inhibitors than antiviral drugs and antibiotics. 12 In addition, treatment based on combination of anti-inflammatories (corticoid therapy) and anticoagulants leads to less ventilation, hospitalization, and finally lower morbidity and mortality. 13 It is suggested that the use of anti-inflammatory agents, such as corticosteroids (CS) or tosilizumab (TCZ), might be useful for the treatment of advanced stage of COVID-19 to reduce the necessity of mechanical ventilators and lower the risk of mortality. 14 Mechanism of corticosteroid is shown in Figure 1 . According to the results of some studies, treatment of COVID-19 patients with corticosteroids alone or tosilizumab might lead to increased survival. It seems that combination therapy of tosilizumab and corticosteroids can be used to modulating inflammation of lung injury. 15 Therefore, the aim of this meta-analysis study is to determine the role of combination therapy with tosilizumab and corticosteroids in COVID-19 patients. In this study, the published articles were collected from databases such as Science direct, Pub med, Web of Science, Scopus, Cochrane, and Google scholar between January 2019 and April 2021. The search strategy was performed using English keywords as well as a combination of important, and sensitive words. Search was done using the keywords "Tosilizumab," "Clinical trial," "COVID-19," "RR," "SARS-COV-2," "Risk Ratio," "Steroids," "Corticosteroids," "Methylprednisolone" by adding AND, OR in the title and abstract. In addition, the reference of articles was examined for the increase of search sensitivity. Finally, all references are entered into reference management software (EndNote). In this study, the search strategy tool (PICO) aimed to determine the impact of patient (P), intervention (I), comparison (C), and outcome (O). "P" signifies COVID-19 patients in studies; "I" means intervention with tosilizumab and steroids. "C" In this study, the full text or summary of articles, documents, and reports were screened and extracted. First, the irrelevant articles were removed from this study. Then, by reviewing and studying, the case reports and review studies were omitted. Finally, according to inclusion and exclusion criteria, data were extracted from full-text articles. Screening and data extraction were performed by two independent reviewers based on article title, first author's name, year of study, journal name, place of study, type of study, the total number of patients in TCZ +/ CS group, number of recovered patients in TCZ +/ CS group, number of deaths in TCZ +/ CS group, the total number of patients in the control group, number of recovered patients in the control group, and number of deaths in the control group were entered into the excel. According to this point that all the prospective cohort studies entered into a meta-analysis, the Newcastle-Ottawa scale (NOS) checklist 16 was used for the evaluation of the quality of articles. In this checklist, nine questions were presented that cover the type of study, sample size, study objectives, study population, sampling method, data analysis method, presentation of findings in an appropriate way, and presentation of results based on objectives. Each question was assigned a score. If a study scored at least 5 points, it was included in this study. Stata ver. 14 package (Stata Corp) was used to analyze the obtained data. Data were weighted and combined based on the inverse variance. Cochran (Q) and I 2 tests were used to determine the heterogeneity index between studies. Based on the heterogeneity results, a random effect model was used to estimate the risk of death in different types of treatment groups. Publication bias was estimated through Egger's test and the impact of each study on the overall estimate was assessed by sensitivity analysis. In this study, 1446 articles were found by using different databases. After screening and removing duplicate records, the remaining 331 articles were evaluated for eligibility. Finally, by removing the unrelated records, five studies were included in our meta-analysis ( Figure 2 ). In addition, according to the NOS checklist, the quality score of the studies was 5 or higher. In five studies, COVID-19 patients treated with corticosteroids and tocilizumab were compared with patients who received tocilizumab alone. 15, [17] [18] [19] [20] In these five studies, 460 patients received corticosteroids and tocilizumab and 303 patients treated with tocilizumab alone ( Table 1 ). In four studies, 15,18-20 the risk of death was lower in the corticosteroids and tocilizumab group than those treated with tocilizumab alone, and the differences in two of these four studies were significant. 15,20 . In one study, 17 the risk of death was significantly higher in patients treated with corticosteroids and tocilizumab than the tocilizumab alone group. Combining the results of these 5 studies using the random- (Table 3 ). In four studies, 15,18-21 the risk of mortality in COVID-19 patients who received corticosteroids and tocilizumab was significantly lower than the control group. In addition, in Rodríguez-Baño J study, there were no statistically significant differences between the two groups for death (combination of corticosteroids and tocilizumab compared to the control group). 17 Combining the results of these 5 studies using the random- (Table 4 ). The aim of this meta-analysis study was to evaluate the efficacy of corticosteroids and tocilizumab on the risk of death in COVID-19 patients. The results showed that the risk of mortality in patients who were treated with corticosteroids and tocilizumab was lower than (26%) in patients treated with tocilizumab alone and control groups. There was no statistically significant difference. By omitting the Rodriguez-Bano, study the risk of death in patients treated with corticosteroids and tocilizumab was significantly lower than (47%) in patients treated with tocilizumab alone. In addition, the risk of mortality in patients who were treated with corticosteroids and tocilizumab was significantly lower than (52%) the control group (the group that received routine treatment). At the beginning of the epidemic, corticosteroid therapy was one of the most controversial drugs against COVID-19. 21 In general, steroids, including corticosteroids and glucocorticoids (dexamethasone and methylprednisolone), are used as immunosuppressive therapies in COVID-19 patients who suffer from severe inflammation by high levels of the proinflammatory cytokines IL-6 and IL-1 and play an important role in reducing mortality and the need for, mechanical ventilation. Steroid treatment also increased COVID-19 patient survival. 22, 23 Tocilizumab, a monoclonal antibody against IL-6, is one of the drugs that was recommended at the beginning of the pandemic in China and Italy to treat patients exhibiting, severe inflammation and elevated ferritin and IL-6 levels (PaO 2 /FiO 2 \150). 24 Observational studies in Spain, Italy, and the United States show that tocilizumab reduces ICU admittances, the need for mechanical ventilation, and mortality in patients when compared with those receiving routine treatment. 14 In addition, another study in Italy suggested that the rate of mortality in the tocilizumab group (179 patients) was significantly lower than the control group (365 patients). 25 Another finding reported that the use of corticosteroids or tocilizumab has been widely used in COVID-19 patients with severe pneumonia. 26 Some studies show that treatment with the combination of corticosteroids and tocilizumab reduces in-hospital mortality. Also, there was no intubation observed during 48 h. 15, 27 In addition, in a study conducted in Italy, the use of these two drugs was investigated either separately or in combination to treat COVID-19 patients. It is found that administration of tocilizumab and steroids led to improve outcomes in COVID-19 patients. 28 better results than when steroids were added at a later stage. 30 On the other hand Rodríguez-Bano showed that mortality rates were higher in patients receiving a combination of corticosteroids and tocilizumab compared to those that received only tocilizumab. This could be due to different times and different doses of drugs. In current study, high doses of corticosteroids were given to patients with hyperinflammatory. 16 The results of the present studies indicate that combination of corticosteroids and tocilizumab is safe and effective in the treatment of COVID-19 patients. The effect of this anti-inflammatory compound treatment requires further RCT studies. This meta-analysis showed that the risk of death in COVID-19 patients who were treated with corticosteroids and tocilizumab was lower than patients treated with tocilizumab alone and control group (26% and 52%, respectively). The authors would like to thank Mazandaran University of Medical Sciences for financial support (IR.MAZUMS.REC.1400.9213). The authors declare that there are no conflict of interests. Mousavi revised the final manuscript. All authors reviewed and approved the final version of the manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. ORCID Tahoora Mousavi http://orcid.org/0000-0003-2505-370X Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet Epidemiological characteristics of COVID-19 in Gansu province Epidemiology and clinical characteristics of COVID-19 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet Clinical and immunological features of severe and moderate coronavirus disease 2019 COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents The pathogenesis and treatment of the Cytokine Storm'in COVID-19 Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study Tocilizumab and steroid treatment in patients with COVID-19 pneumonia Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: an observational study Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients Dexamethasone in hospitalized patients with Covid-19-preliminary report Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab in patients with severe COVID-19: a retrospective cohort study Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital WHO Rapid Evidence Appraisal for COVID-Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Tocilizumab and steroid treatment in patients with COVID-19 pneumonia Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis